Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 222-164-4 | CAS number: 3375-31-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Endpoint summary
Administrative data
Key value for chemical safety assessment
Genetic toxicity in vitro
Description of key information
The genetic toxicity potential of Palladium(II) acetate is determined using an in vitro reverse mutation assay with bacteria according to protocol OECD 471 (GLP compliant). The assay provided no evidence of any
Palladium(II) acetate mutagenic activity.
Link to relevant study records
- Endpoint:
- in vitro gene mutation study in bacteria
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 11 Sept 2019 - 9 Oct 2019
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Remarks:
- Study performed according to GLP
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 471 (Bacterial Reverse Mutation Assay)
- Version / remarks:
- OECD 1997
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Type of assay:
- bacterial reverse mutation assay
- Specific details on test material used for the study:
- Palladium(II) acetate (99.9% purity)
Pd content 48.22% - Species / strain / cell type:
- S. typhimurium TA 1535, TA 1537, TA 98, TA 100 and TA 102
- Metabolic activation:
- with and without
- Metabolic activation system:
- Mammalian liver post-mitochondrial fraction (S-9)
S-9 prepared from male Sprague Dawley rats induced with Aroclor 1254.
S-9 supplied as lyophilized S-9 mix (MutazymeTM), stored frozen at <-10°C, and thawed and reconstituted with purified water to provide a 10% S-9 mix just prior to use.
Each batch was checked by the manufacturer for sterility, protein content, ability to convert ethidium bromide and cyclophosphamide to bacterial mutagens, and cytochrome P-450-catalysed enzyme activities (alkoxyresorufin-O-dealkylase activities).
Treatments were carried out both in the absence and presence of S-9 by addition of either buffer solution or 10% S-9 mix respectively. - Test concentrations with justification for top dose:
- Treatments in this study were performed using suspensions of test item in vehicle up to a maximum concentration of 5000 μg/plate in Experiment 1, in order that initial treatments were performed up to this maximum recommended concentration according to current regulatory guidelines (OECD, 1997).
For Experiment 1 repeat treatments and Experiment 2 the maximum concentration tested was selected on the basis of toxicity seen in Experiment 1.
Toxicity assessed as diminution of background bacterial lawn and/or marke d reduciton in revertant numbers.
Experiment 1: 5, 16, 50, 160, 500, 1600,5000 µg/plate (+ and - S9)
Experiment 1 (repeat) and Experiment 2: 0.65536, 1.6384, 4.096, 10.24, 25.6, 64 and 160 µg/plate (+ and - S9), treatments +S9 further modified by inclusion of pre-incubation step. - Vehicle / solvent:
- Preliminary solubility data indicated that Palladium acetate was soluble in dimethylformamide (DMF) at concentrations equivalent to at least 55.2 mg/mL.
Test article stock solutions were prepared by formulating Palladium acetate under
subdued lighting in DMF with the aid of vortex mixing, ultrasonication and warming
at 37°C (as required) to give the maximum required treatment concentration.
Subsequent dilutions were made using DMF. The test article solutions were protected
from light and used within approximately 4.5 hours of initial formulation. - Negative solvent / vehicle controls:
- yes
- Remarks:
- 0.1 mL DMF
- Positive controls:
- yes
- Remarks:
- 0.05 mL additions
- Positive control substance:
- 9-aminoacridine
- 2-nitrofluorene
- sodium azide
- benzo(a)pyrene
- mitomycin C
- other: 2-aminoanthracene
- Details on test system and experimental conditions:
- 0.1 mL volume additions of test article suspension were used for all treatments.
Plating details:
-0.1 mL of bacterial culture
-0.1 mL of test article suspension/vehicle control or 0.05 mL of positive control
-0.5 mL of 10% S-9 mix or buffer solution,
ollowed by rapid mixing and pouring on to Vogel-Bonner E agar plates. When set, the plates were inverted and incubated protected from light for 3 days in an incubator set to 37°C. Following incubation, these plates were examined for evidence of toxicity to the background lawn, and where possible revertant colonies were counted.
Due to extensive test article related toxicity following these initial Mutation
Experiment 1 treatments, Mutation Experiment 1 repeat treatments were performed in
all the tester strains in order to provide thorough and robust mutation data. These
treatments were performed using the methodology described above for Mutation
Experiment 1, but using lower test article concentrations.
It may be noted that initial Experiment 1 repeat treatments of strain TA102 in the
presence of S-9 were invalidated due to uncharacteristic vehicle control counts (data
not reported). These treatments were repeated (with diagnostic control treatments in
the absence of S-9; data not reported) in order to provide the mutation data for this
strain presented in this report.
As the results of Experiment 1 (and repeat) were negative, treatments in the presence
of S-9 in Experiment 2 included a pre-incubation step. Quantities of test article,
vehicle control solution or positive control, bacteria and S-9 mix detailed above, plus
an additional 0.5 mL of 100 mM sodium phosphate buffer (pH 7.4), were mixed
together and placed in an orbital incubator set to 37°C for 20 minutes, before the
addition of 2 mL molten agar at 45±1°C. Plating of these treatments then proceeded
as for the normal plate-incorporation procedure. In this way, it was hoped to increase
the range of mutagenic chemicals that could be detected in the assay.
The addition of 0.5 mL of 100 mM sodium phosphate buffer (pH 7.4) to these
Experiment 2 treatments in the presence of S-9 was employed to reduce the solvent
concentration during the pre-incubation period. DMF, and some other organic
solvents, are known to be near to toxic levels when added at volumes of 0.1 mL in
this assay system when employing the pre-incubation methodology. By employing the
modification indicated, the DMF concentration in the pre-incubation mix was
decreased, and it was hoped that this would minimise or eliminate any toxic effects of
the solvent that may have otherwise occurred. In order to ‘correct’ for the additional
volume in the pre-incubation mix, these were plated out using 2 mL of 1.125% soft
agar, therefore the additions to each plate were comparable to that of the plateincorporation
treatments. - Rationale for test conditions:
- For valid data, the test article was considered to be mutagenic if:
1. A concentration related increase in revertant numbers was ≥1.5-fold (in strain TA102), ≥2-fold (in strains TA98 or TA100) or ≥3-fold (in strains TA1535 or TA1537) the concurrent vehicle control values
2. Any observed response was reproducible under the same treatment conditions.
The test article was considered positive in this assay if both of the above criteria were met.
The test article was considered negative in this assay if none of the above criteria were met. - Statistics:
- triplicate plates per concentration.
Individual plate counts were recorded separately and the mean and standard deviation of the plate counts for each treatment were determined. Control counts were compared with the laboratory’s historical control ranges.
The presence or otherwise of a concentration response was checked by non-statistical analysis, up to limiting levels (for example toxicity, precipitation or 5000 μg/plate). However, adequate interpretation of biological relevance was of critical importance. - Species / strain:
- S. typhimurium TA 102
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not examined
- True negative controls validity:
- not examined
- Positive controls validity:
- valid
- Species / strain:
- S. typhimurium TA 100
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not examined
- True negative controls validity:
- not examined
- Positive controls validity:
- valid
- Species / strain:
- S. typhimurium TA 98
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not examined
- True negative controls validity:
- not examined
- Positive controls validity:
- valid
- Species / strain:
- S. typhimurium TA 1537
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not examined
- True negative controls validity:
- not examined
- Positive controls validity:
- valid
- Species / strain:
- S. typhimurium TA 1535
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not examined
- True negative controls validity:
- not examined
- Positive controls validity:
- valid
- Additional information on results:
- Although in each experiment the change in pH units across the concentration range was >1, lower pH values were expected with increasing
Pd acetate concentration. These data were not considered to provide any concerns for the assay or test compound, and so treatments proceeded as planned. - Remarks on result:
- no mutagenic potential (based on QSAR/QSPR prediction)
- Conclusions:
- It was concluded that Palladium acetate did not induce mutation in five histidinerequiring
strains (TA98, TA100, TA1535, TA1537 and TA102) of Salmonella
typhimurium when tested under the conditions of this study. These conditions
included treatments up to toxic concentrations in the absence and in the presence of a
rat liver metabolic activation system (S-9). - Executive summary:
Palladium acetate was assayed for mutation in five histidine-requiring strains (TA98, TA100, TA1535, TA1537 and TA102) of Salmonella typhimurium, both in the absence and in the presence of metabolic activation by an Aroclor 1254-induced rat liver post-mitochondrial fraction (S-9), in two separate experiments.
All Palladium acetate treatments in this study were performed using formulations prepared in dimethylformamide (DMF).
Mutation Experiment 1 treatments of all the tester strains were performed in the absence and in the presence of S-9, using final concentrations of Palladium acetate at 5, 16, 50, 160, 500, 1600 and 5000 μg/plate. Following these treatments, evidence of toxicity was observed in all the tester strains and extended down to either 50 μg/plate or 160 μg/plate in each case. Due to the extent of this toxicity, mutation data were available from fewer than 5 analysable concentrations, and therefore all strain treatments were repeated to provide a thorough and robust assessment of the mutagenicity of the test article. Mutation Experiment 1 repeat treatments of all the tester strains were therefore performed in the absence and in the presence of S-9 using
final concentrations of Palladium acetate at 0.65536, 1.6384, 4.096, 10.24, 25.6, 64 and 160 μg/plate, these concentrations being selected to test up to the lower limit of toxicity. Following these treatments, evidence of toxicity was observed in all strains in the absence and presence of S-9 and extended down to 25.6, 64 or 160 μg/plate in each strain. Mutation data were available from at least 5 analysable concentrations in each strain.
Mutation Experiment 2 treatments of all the tester strains were performed in the absence and in the presence of S-9. The maximum test concentration of 160 μg/plate was retained for all strains, as were the rest of the treatment concentrations.
Treatments in the presence of S-9 were modified by the inclusion of a pre-incubation step. In this way, it was hoped to increase the range of mutagenic chemicals that could be detected using this assay system. Following these treatments, evidence of toxicity was again observed in all the strains in the absence and presence of S-9 and extended down to either 25.6 μg/plate, 64 μg/plate or 160 μg/plate in each case. Mutation data were available from at least 5 analysable concentrations from each strain. The test article was completely soluble in the aqueous assay system at all concentrations treated, in each of the experiments performed. Vehicle and positive control treatments were included for all strains in all experiments. The mean numbers of revertant colonies were comparable with acceptable ranges for vehicle control treatments, and were elevated by positive control treatments.
Following Palladium acetate treatments of all the test strains in the absence and presence of S-9, no notable or concentration-related increases in revertant numbers were observed, and none that were ≥1.5-fold (in strain TA102), ≥2-fold (in strains TA98 or TA100) or ≥3-fold (in strains TA1535 or TA1537) the concurrent vehicle control. This study was considered therefore to have provided no evidence of any palladium acetate mutagenic activity in this assay system.
Reference
Following test item treatments of all the test strains in the absence and presence of S-9, no notable or concentration-related increases in revertant numbers were observed, and none that were ≥1.5-fold (in strain TA102), ≥2-fold (in strains TA98 and TA100) or ≥3-fold (in strains TA1535 and TA1537) the concurrent vehicle control. This study was considered therefore to have provided no evidence of any test item mutagenic activity in this assay system.
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (negative)
Genetic toxicity in vivo
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Justification for classification or non-classification
In vitro testing provided no evidence of any palladium(II) acetate mutagenic activity, and the substance does not require a classification for this endpoint.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
